Identification of lipid binding and lipoprotein lipase activation domains of human apoAV

Chemistry and Physics of Lipids

Volumn 143, Issue 1-2, 2006, Pages 22-28

  Sun, Guotao ^a   Bi, Nan ^a   Li, Guoping ^a   Zhu, Xuewei ^a   Zeng, Wuwei ^a   Wu, Gang ^a   Xue, Hong ^a   Chen, Baosheng ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Apolipoprotein AV; Lipid; Lipoprotein lipase; Secondary structure

Indexed keywords

APOLIPOPROTEIN A5; LIPID; LIPOPROTEIN LIPASE;

AMINO ACID SEQUENCE; ARTICLE; CIRCULAR DICHROISM; CORRELATION ANALYSIS; ENZYME ACTIVATION; ESCHERICHIA COLI; LIPID ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; PROTEIN STRUCTURE; STATISTICAL SIGNIFICANCE; WILD TYPE;

ANIMALS; APOLIPOPROTEINS; APOLIPOPROTEINS A; CATTLE; CIRCULAR DICHROISM; ENZYME ACTIVATION; GENE EXPRESSION; HUMANS; KINETICS; LIPID METABOLISM; LIPOPROTEIN LIPASE; MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION;

ESCHERICHIA COLI;

EID: 33746275220     PISSN: 00093084     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chemphyslip.2006.04.004     Document Type: Article

References (33)

1. Baroukh N., Bauge E., Akiyama J., Chang J., Afzal V., Fruchart J.C., Rubin E.M., Fruchart-Najib J., and Pennacchio L.A. Analysis of apolipoprotein A5, c3, and plasma triglyceride concentrations in genetically engineered mice. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1297-1302
2. Beckstead J.A., Oda M.N., Martin D.D., Forte T.M., Bielicki J.K., Berger T., Luty R., Kay C.M., and Ryan R.O. Structure-function studies of human apolipoprotein AV: a regulator of plasma lipid homeostasis. Biochemistry 42 (2003) 9416-9423
3. Bi N., Yan S.K., Li G.P., Yin Z.N., and Chen B.S. A single nucleotide polymorphism-1131T > C in the apolipoprotein A5 gene is associated with an increased risk of coronary artery disease and alters triglyceride metabolism in Chinese. Mol. Genet. Metab. 83 3 (2004) 280-286
4. Chen Y.H., Yang J.T., and Martinez H.M. Determination of the secondary structures of proteins by circular dichroism and optical rotatory dispersion. Biochemistry 11 (1972) 4120-4131
5. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am. J. Cardiol. 86 (2000) 943-949
6. Edelstein C., and Scanu A.M. Effect of guanidine hydrochloride on the hydrodynamic and thermodynamic properties of human apolipoprotein A-I in solution. J. Biol. Chem. 255 (1980) 5747-5754
7. Endo K., Yanagi H., Araki J., Hirano C., Yamakawa-Kobayashi K., and Tomura S. Association found between the promoter region polymorphism in the apolipoprotein AV gene and the serum triglyceride level in Japanese school children. Hum. Genet. 111 (2002) 570-572
8. Fruchart-Najib J., Bauge E., Niculescu L.S., Pham T., Thomas B., Rommens C., Majd Z., Brewer B., Pennacchio L.A., and Fruchart J.C. Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem. Biophys. Res. Commun. 319 2 (2004) 397-404
9. Kao J.T., Wen H.C., Chien K.L., Hsu H.C., and Lin S.W. A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. Hum. Mol. Genet. 12 (2003) 2533-2539
10. H-dependent promoter activation in Bacillus subtilis. J. Bacteriol. 186 (2004) 1078-1083
11. Liu L.M., and Severson D.L. Endothelial binding sites for lipoprotein lipase are not diminished in perfused hearts from diabetic rats. Can. J. Physiol. Pharmacol. 74 (1996) 1204-1209
12. Li G.P., Wang J.Y., Yan S.K., Chen B.S., Xue H., and Wu G. Genetic effect of two polymorphisms in the apolipoprotein A5 gene and apolipoprotein C3 gene on serum lipids and lipoproteins levels in a Chinese population. Clin. Genet. 65 6 (2004) 470-476
13. Lookene A., Beckstead J.A., Nilsson S., Olivecrona G., and Ryan R.O. Apolipoprotein AV-heparin interactions: implications for plasma lipoprotein metabolism. J. Biol. Chem. 280 27 (2005) 25383-25387
14. Marcais C., Verges B., Charriere S., Pruneta V., Merlin M., Billon S., Perrot L., Drai J., Sassolas A., Pennacchio L.A., Fruchart-Najib J., Fruchart J.C., Durlach V., and Moulin P. Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J. Clin. Invest. 115 (2005) 2862-2869
15. Merkel M., Loeffler B., Kluger M., Fabig N., Geppert G., Pennacchio L.A., Laatsch A., and Heeren J. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J. Biol. Chem. 280 (2005) 21553-21560
16. Narayanaswami V., et al. Molecular basis of exchangeable apolipoprotein function. Biochim. Biophys. Acta 1483 1 (2000) 15-36
17. Oliva C.P., Pisciotta L., Li Volti G., Sambataro M.P., Cantafora A., Bellocchio A., Catapano A., Tarugi P., Bertolini S., and Calandra S. Inherited apolipoprotein AV deficiency in severe hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 411-417
18. Olivecrona G., and Beisiegel U. Lipid binding of apolipoprotein CII is required for stimulation of lipoprotein lipase activity agaist apolipoprotein CII-deficient chylomicrons. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 1545-1549
19. Pace C.N. Determination and analysis of urea and guanidine hydrochloride denaturation curves. Methods Enzymol. 131 (1986) 266-280
20. Palgunachari M.N., Mishra V.K., Lund-Katz S., Phillips M.C., Adeyeye S.O., Alluri S., Anantharamaiah G.M., and Segrest J.P. Only the two end helixes of eight-tandem amphipathic helical domains of human apo A-I have significant lipid affinity-implications for HDL assembly. Arterioscler. Thromb. Vasc. Biol. 16 (1996) 328-338
21. Pennacchio L.A., and Rubin E.M. Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in humans and mice. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 529-534
22. Pennacchio L.A., Olivier M., Hubacek J.A., Cohen J.C., Cox D.R., Fruchart J.C., Krauss R.M., and Rubin E.M. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294 (2001) 169-173
23. Saito H., Dhanasekaran P., Nguyen D., Holvoet P., Lund-Katz S., and Phillips M.C. Domain structure and lipid interaction in human apolipoproteins A-I and E, a general model. J. Biol. Chem. 278 (2003) 23227-23232
24. Schaap F.G., Rensen P.C.N., Voshol P.J., Vrins C., van der Vliet H.N., Chamuleau R.A.F.M., Havekes L.M., Groen A.K., and van Dijk K.W. ApoAV reduces plasma triglycerides by inhibiting very low-density lipoprotein-triglyceride production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J. Biol. Chem. 279 (2004) 27941-27947
25. Seda O., and Sedova L. New apolipoprotein AV: comparative genomics meets metabolism. Physiol. Res. 52 (2003) 141-146
26. Sparks D.L., Lund-katz S., and Phillips M.C. The charge and structural stability of apolipoprotein A-I in discoidal and spherical recombinant high-density lipoprotein particles. J. Biol. Chem. 267 (1992) 25839-25847
27. Talmud P.J., Martin S., Taskinen M.R., Frick M.H., Nieminen M.S., Kesaniemi Y.A., Pasternack A., Humphries S.E., and Syvanne M. APOA5 gene variants, lipoprtein distribution, and progression of coronary heart disease: result from the LOCAT study. J. Lipid Res. 45 (2004) 750-756
28. Valentine C.M., and Durrington P.N. Apolipoprotein A5 and hypertriglyceridemia. Clin. Chem. 51 (2005) 295-297
29. Van der Vliet H.N., Sammels M.G., Leegwater A.C., Levels J.H., Reitsma P.H., Boers W., and Chamuleau R.A. Apolipoprotein AV: a novel apolipoprotein associated with an early phase of liver regeneration. J. Biol. Chem. 276 (2001) 44512-44520
30. Van der Vliet H.N., Schaap F.G., Levels J.H., Ottenhoff R., Looije N., Wesseling J.G., Groen A.K., and Chamuleau R.A. Adenoviral overexpression of apolipoprotein AV reduces serum levels of triglycerides and cholesterol in mice. Biochem. Biophys. Res. Commun. 295 (2002) 1156-1159
31. Weinberg R.B., Cook V.R., Beckstead J.A., Martin D.D., Gallagher J.W., Shelness G.S., and Ryan R.O. Structure and interfacial properties of human apolipoprotein AV. J. Biol. Chem. 278 (2003) 34438-34444
32. Whitman S.C., Miller D.B., Wolfe B.M., Hegele R.A., and Huff M.W. Uptake of type III hypertriglyceridemic VLDL by macrophages is enhanced by oxidation, especially after remnant formation. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 1707-1715
33. Zhu X.W., Wu G., Zeng W.W., Xue H., and Chen B.S. Cysteine mutants of human apolipoprotein A-I: a study of secondary structural and functional properties. J. Lipid Res. 46 (2005) 1303-1311